Together, these results demonstrate that oral baricitinib effectively inhibits the JAK/STAT pathway in mouse models of influenza infection and post‐influenza MRSA pneumonia. Here, SOAT1 is linked to Methicillin-Resistant Staphylococcus Aureus Pneumonia.